看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。' F$ S" C% s6 t1 ]0 K4 s9 E
9 V- ?% ]4 m$ w/ G0 ?# w. N) h5 e: ?) U& O4 F- k N, I+ f
Currently available feasibility data for possible combination strategies.
/ W2 p* N' \# m4 K————————————————————————————————" m* g( w& T y* Z4 [
Combination Feasibility according to preliminary data
( V2 H8 x& B5 ~( o& `5 r0 j' `# m——————————————————————————————————
G0 V+ {! K9 x' ~+ n2 L" mBevacizumab + sorafenib Yes, reduced dose
- t' r: x) s- iBevacizumab + sunitinib† No * q. ]8 d' c& H. D: J- I* M. e
Bevacizumab + temsirolimus Yes
3 ]# N9 F9 d2 Z$ Q8 _3 m/ H, aBevacizumab + everolimus Yes " Z7 P k) V2 `; B+ e* M5 X
Sorafenib + sunitinib ?
; ^0 ~3 v/ Q TSorafenib + temsirolimus Yes, reduced dose 0 T/ o9 V+ N) [# }+ Y3 v- L1 n
Sorafenib + everolimus Yes, reduced dose
X2 P# L$ @% U% H% VSunitinib + temsirolimus† No
# ^/ l7 y6 T2 e2 Y% U! xSunitinib + everolimus ? 5 i! }5 m- t2 O2 O% d5 Z( p7 \
Temsirolimus + everolimus ? ; Y; w9 E( _$ O$ o5 F* U4 w
————————————————————, x" G( U7 D% P% ?" M( c# I% {
†Led to US FDA warning.' }5 a; \+ R% Z
?: As yet unattempted combination.% Z9 k l" w; l% W: V/ H
|